

**Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees**

Grabski M, Waldron J, Freeman TP, van Laar M, Curran HV.

International journal on drug policy

2022; 102:e103612

**ARTICLE IDENTIFIERS**

DOI: 10.1016/j.drugpo.2022.103612

PMID: 35151083

PMCID: not available

**JOURNAL IDENTIFIERS**

LCCN: not available

pISSN: 0955-3959

eISSN: 1873-4758

OCLC ID: 22592772

CONS ID: not available

US National Library of Medicine ID: 9014759

This article was identified from a query of the SafetyLit database.